BARD1 splice variants display mislocalization in breast cancer cells and can alter the apoptotic response to cisplatin

• Published in: Cancer letters 2016-10, Vol.381 (1), p.149-155
• Main Authors: Marzec, Kamila A, Martino-Echarri, Estefania, Irminger-Finger, Irmgard, Henderson, Beric R
• Format: Article
• Language: English
• Subjects: Active Transport, Cell Nucleus; Alternative Splicing; Antineoplastic Agents - pharmacology; Apoptosis; Apoptosis - drug effects; Bacterial Proteins - genetics; Bacterial Proteins - metabolism; BARD1; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - enzymology; Breast Neoplasms - genetics; Breast Neoplasms - pathology; Cisplatin; Cisplatin - pharmacology; Cytoplasm - enzymology; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Hematology, Oncology and Palliative Medicine; Humans; Kinases; Laboratories; Luminescent Proteins - genetics; Luminescent Proteins - metabolism; MCF-7 Cells; Nuclear localization; Plasmids; Protein Isoforms; Recombinant Fusion Proteins - metabolism; Signal Transduction - drug effects; Splice variants; Transfection; Tumor Suppressor Proteins - genetics; Tumor Suppressor Proteins - metabolism; Ubiquitin-Protein Ligases - genetics; Ubiquitin-Protein Ligases - metabolism
• ISSN: 0304-3835; 1872-7980
• DOI: 10.1016/j.canlet.2016.07.034

Highlights • BARD1 splice variants display altered subcellular localization • BARD1- beta and -omega lack a nuclear export sequence and accrue in the nucleus • Nuclear-located beta and omega isoforms are less apoptotic in MCF-7 cells • BARD1-epsilon lacks a nuclear localization signal and accumulates in the cytoplasm • BARD1 variant mis-localization can alter breast cancer cell apoptotic responses